1-(4-溴苯基)-5-氧代吡咯烷-3-羧酸 | 91348-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(4-溴苯基)-5-氧代吡咯烷-3-羧酸
• 英文名称: 1-(4-bromophenyl)-5-oxopyrrolidine-3-carboxylic acid
• CAS: 91348-51-5
• 化学式: C₁₁H₁₀BrNO₃
• mdl: MFCD00448856
• 分子量: 284.109
• InChiKey: MDFOXHGBFTXKQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933790090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(4-Bromophenyl)-5-oxopyrrolidine-3-carboxylic acid
Synonyms: 1-(4-Bromophenyl)-2-pyrrolidinone-4-carboxylic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-Bromophenyl)-5-oxopyrrolidine-3-carboxylic acid
CAS number: 91348-51-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H10BrNO3
Molecular weight: 284.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(4-溴苯基)-5-氧代吡咯烷-3-羧酸 在 硫酸 作用下， 以 甲醇 为溶剂， 以91%的产率得到methyl 1-(4-bromophenyl)-5-oxopyrrolidine-3-carboxylate
  参考文献：
  名称：

  [EN] LACTAMS AS INHIBITORS OF ROCK
  [FR] LACTAMES UTILISÉS EN TANT QU'INHIBITEURS DE RHO-KINASES (ROCK)

  摘要：

  本发明提供了化合物的结构式（I）：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包括这些化合物的药物组合物以及使用这些药物治疗心血管、平滑肌、肿瘤、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。

  公开号：

  WO2016144936A1
• 作为产物：
  描述：

  衣康酸 、 4-溴苯胺 以92%的产率得到1-(4-溴苯基)-5-氧代吡咯烷-3-羧酸
  参考文献：
  名称：

  发现具有潜在诱导的系统抗性的新型植物活化剂和支架：从茉莉酸到吡咯烷酮†

  摘要：

  由于病原体，昆虫和某些特定微生物的感染，或者经过特定化学物质的处理，植物会发展出多方面的系统抗性。1其中，系统性获得性抵抗力（SAR）和诱导性系统抵抗力（ISR）2是两个最重要的类型。为了激活它们，已经基于SA途径开发了大量化学诱导剂。但是，对于新的植物激活剂，很少研究JA途径。在这项研究中，从JA及其类似物出发，基于分子三维形状和药效基团相似性比较（SHAFTS），预测了一种新的先导化合物吡咯烷酮，它将作为一种植物激活剂的新支架，并形成一系列1-苯基设计并合成了-5-吡咯烷酮-3-羧酸衍生物。对生物活性进行了评估，大多数化合物均显示出令人满意的活性。特别是化合物7-11在体外几乎没有显示 活性，但对被测疾病具有优异的疗效，并证实了虚拟筛选结果的预测，这促进了SHAFTS在农药开发中的应用。

  DOI：

  10.1039/c6md00261g

文献信息

• [EN] PYRROLIDINE GPR40 MODULATORS<br/>[FR] MODULATEURS DE GPR40 À BASE DE PYRROLIDINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015171757A1

  公开（公告）日：2015-11-12

  The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.

  本发明提供了式(I)的化合物：或其立体异构体、互变异构体、药用盐、多晶型或溶剂化物，其中所有变量均如本文所述定义。这些化合物是GPR40 G蛋白偶联受体的调节剂，可用作药物。
• 芳基烷基胺化合物、其制备方法及其在医药上的应用
  申请人：上海拓界生物医药科技有限公司

  公开号：CN113121398B

  公开（公告）日：2023-06-20

  本公开涉及芳基烷基胺化合物、其制备方法及其在医药上的应用。特别的本公开的化合物适合作为钙敏感受体激动剂，可用作治疗或预防通过激活CaSR和/或抑制PTH产生而改善病症的药物的有效成分，如式(I)，基团的定义如说明书中所述。
• IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20150051190A1

  公开（公告）日：2015-02-19

  The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R 1 , G, T, Y 1 , Y 2 , Y 3 , and Y 4 are as defined herein.

  本发明旨在提供一种化合物或其药理学上可接受的盐，通过其对ROS1激酶酶活性的抑制作用和NTRK激酶酶抑制作用，在肿瘤治疗中具有用途。本发明提供了一种具有通式(I)所代表的咪唑并[1,2-b]吡啶结构的化合物或其药理学上可接受的盐，以及包含该化合物的药物组合物。在该式中，R1、G、T、Y1、Y2、Y3和Y4如本处所定义。
• Pyrrolidinone-bearing methylated and halogenated benzenesulfonamides as inhibitors of carbonic anhydrases
  作者：Irena Vaškevičienė、Vaida Paketurytė、Nikita Pajanok、Šarūnas Žukauskas、Birutė Sapijanskaitė、Kristina Kantminienė、Vytautas Mickevičius、Asta Zubrienė、Daumantas Matulis

  DOI：10.1016/j.bmc.2018.12.011

  日期：2019.1

  inhibitors of the twelve catalytically active human carbonic anhydrase (CA) isoforms. Observed binding affinities were determined by fluorescent thermal shift assay and intrinsic binding affinities representing the binding of benzenesulfonamide anion to the Zn(II)-bound water form of CA were calculated. Introduction of dimethyl groups into benzenesulfonamide ring decreased the binding affinity to almost all

  两个系列的苯磺酰胺轴承甲基在邻位/邻位或/元邻位和在吡咯烷酮部分对位的合成和作为12催化活性的人类碳酸酐酶（CA）的同种型的抑制剂测试。通过荧光热移测定法测定观察到的结合亲和力，并计算代表苯磺酰胺阴离子与CA的Zn（II）结合水形式结合的固有结合亲和力。将二甲基基团引入苯磺酰胺环可降低与几乎所有CA同工型的结合亲和力，但可提高对一种CA同工型的选择性。在氯基元2,6-二甲基苯磺酰胺衍生物的位置不影响与CA I的结合，但增加了对所有其他CA的亲和力，尤其是CA VII和CA XIII（最多500倍）。所述化合物可用于对特定CA同工型具有更高选择性的CA抑制剂的进一步开发。
• Site-Specific Synthesis of β-Fluorinated γ-Butyrolactams via Decarboxylative Fluorination of β-Carboxyl-γ-Butyrolactams
  作者：Supasorn Phae-nok、Manat Pohmakotr、Chutima Kuhakarn、Vichai Reutrakul、Darunee Soorukram

  DOI：10.1002/ejoc.201900685

  日期：2019.8.7

  The direct and site‐specific synthesis of β‐fluorinated γ‐butyrolactams via AgNO3 mediated decarboxylative fluorination of β‐carboxyl‐γ‐butyrolactams using Selectfluor® as a fluorine source was described. The β‐fluorinated γ‐butyrolactams including chiral derivatives were obtained in moderate to good yields.

  描述了使用Selectfluor®作为氟源，通过AgNO 3介导的β-羧基-γ-丁内酰胺的直接脱羧氟化反应，直接合成β-氟化的γ-丁内酰胺。包括手性衍生物在内的β-氟化γ-丁内酰胺的收率中等至良好。